Molecule News and Research

RSS

Convergence initiates CNV1014802 Phase II study in lumbosacral radiculopathy

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the Phase II proof of concept study with CNV1014802 for treating pain associated with lumbosacral radiculopathy (LSR) has started.

19 Jul 2011

Scientists define structure of astrovirus that causes juvenile diarrhea

Rice University scientists have defined the structure -- down to the atomic level -- of a virus that causes juvenile diarrhea. The research may help direct efforts to develop medications that block the virus before it becomes infectious.

19 Jul 2011

Stimulant addiction from bath salts causing serious and long term problems

A new stimulant addiction is causing concern among emergency doctors. At Schuylkill Medical Center in Pottsville, Pa. people were arriving so agitated, violent and psychotic that a small army of medical workers was needed to hold them down. They had taken new stimulant drugs that people are calling “bath salts,” and sometimes even large doses of sedatives failed to quiet them.

18 Jul 2011

Disrupting protein components kills mosquitoes

Mosquitoes die soon after a blood meal if certain protein components are experimentally disrupted, a team of biochemists at the University of Arizona has discovered.

18 Jul 2011

Sofinnova Ventures leads $44 million Series B private equity financing for SARcode Bioscience

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing. The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

18 Jul 2011

New DNA sequencer will provide deeper insight into gene regulation

The Berlin Institute for Medical Systems Biology (BIMSB) of the Max Delbr-ck Center for Molecular Medicine (MDC) in Berlin, Germany, will be the first academic research institution in Continental Europe to acquire a novel DNA sequencer enabling the sequencing of single DNA molecules in real time.

16 Jul 2011

Stored red blood cells lose ability to release key anti-adhesive molecule

Donated red blood cells lose a key feature that diminishes their lifesaving power the longer they have been stored, according to researchers at Duke University Medical Center.

16 Jul 2011

Study sheds light on the way antibodies distinguish between different 'biomarkers'

A new research paper sheds light on the way antibodies distinguish between different but closely related 'biomarkers' - proteins which reveal information about the condition of the human body.

15 Jul 2011

E-cadherin may regulate up to 25% of genes within embryonic stem cells

A protein molecule that 'glues' cells together and so has a key role in cancer is also responsible for many other important functions of cells, a new study has found.

15 Jul 2011

UW scientists determine atomic architecture of sodium channel

Scientists at the University of Washington (UW) in Seattle have determined the atomic architecture of a sodium channel. The achievement opens new possibilities for molecular medicine researchers around the world in designing better drugs for pain, epilepsy, and heart rhythm disturbances.

14 Jul 2011

Cornell grants ChromaDex worldwide rights to novel manufacturing process for nicotinamide riboside

ChromaDex Corp. today announced that Cornell University has granted the natural products company ChromaDex exclusive worldwide rights to a novel manufacturing process for nicotinamide riboside (NR).

14 Jul 2011

Adamis receives European patent for novel cell-based cancer vaccine technology

Adamis Pharmaceuticals Corporation, today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe.

14 Jul 2011

USFDA approves Dr. Reddy's ANDA for Fondaparinux Sodium Injection

Dr. Reddy's Laboratories and Alchemia Limited, Brisbane, Australia announced today that Dr. Reddy's has received final approval of Dr. Reddy's ANDA for Fondaparinux Sodium Injection, a bioequivalent generic version of Arixtra, in the US market on July 11, 2011 by the United States Food & Drug Administration.

13 Jul 2011

UNC receives $32 million federal grant to eradicate HIV infection

Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy.

12 Jul 2011

SUMO molecules might prevent protein aggregations that typify PD

A small protein called SUMO might prevent the protein aggregations that typify Parkinson's disease (PD), according to a new study in the July 11, 2011, issue of The Journal of Cell Biology.

12 Jul 2011

Two studies on childhood leukemia

A difficult-to-treat form of childhood leukemia relies on changes in the structure of DNA - so-called epigenetic changes - to wreak genomic havoc within white blood cells, according to one of two studies conducted by a research team at Children's Hospital Boston and Dana-Farber Cancer Institute.

12 Jul 2011

Cancer Cell publishes Epizyme and collaborators' breakthrough research on MLL

Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer and rare disease patients, and its collaborators announced the publication in Cancer Cell of breakthrough research in the treatment of MLL-rearranged leukemia (MLL), a genetically-defined subset of acute lymphoblastic leukemia and acute myelogenous leukemia.

12 Jul 2011

Federal funds may help Gladstone to solve problem of HIV latency

The Gladstone Institutes will receive funds totaling $5.6 million over five years as part of the first-ever major funding initiative focusing on HIV eradication.

12 Jul 2011

NIAID awards $14 million a year for new HIV research

Three research teams focused on developing strategies that could help to rid the body of HIV are receiving grants totaling more than $14 million a year, for up to five years, the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announced today.

11 Jul 2011